Headlands Research, a clinical trial site network with locations across the United States and Canada, is launching its newest ...

After a few years in biotech, Mike Quigley, Ph.D., is returning to the pharma fold, taking up the top science spot at Sanofi.

Roche is rolling out what it describes as a new type of infectious disease diagnostic in Europe, with a single test capable ...

Listening to music while working may one day become a two-way street. | Neurable is putting forward a pair of headphones ...

Recently debuted Metsera is unfolding some phase 1 data for its GLP-1 receptor agonist, revealing a 7.5% reduction in body ...

Biogen and UCB’s gamble on advancing into phase 3 on the back of a failed study looks to have paid off, with the partners ...

Wave’s result is in line with the data that supported accelerated approval of NS Pharma’s exon 53 DMD drug Viltepso. NS ...

Novartis has inked a deal potentially worth more than $1 billion with Flagship-founded Generate:Biomedicines to develop ...

Italian biotech Aptadir Therapeutics has launched with the promise that its pipeline of preclinical RNA inhibitors could ...

The Sanofi equity investment means the Big Pharma will receive exclusive rights of first negotiation surrounding VTX3232, an ...

Context Therapeutics is building up its bank of bispecific antibody candidates. | Context Therapeutics is building up its ...

The stroke devicemaker Route 92 Medical has raised $50 million in funds, as it looks to expand the worldwide commercial reach ...